R.A. De Boer

Rudolf de Boer graduated as MD in 1998 from the University of Groningen, the Netherlands. Subsequently, he enrolled in a PhD program and finished his thesis in 2002. He then was appointed as a postdoctoral fellow (2002-2003) at Harvard Medical School in Boston. Upon his return, he specialized in Cardiology, and completed his training in 2008.

He was appointed as staff cardiologist in the department of Cardiology of the University Medical Center Groningen. His subspecialty is inherited heart diseases and heart failure. He developed a research line in translational cardiology, with focus on myocardial fibrosis, biomarkers, the interaction between diabetes and heart failure, and cardio-oncology.

In 2013, de Boer was appointed as professor in Translational Cardiology at the University of Groningen and became the chair of experimental cardiology. In 2022, he was appointed as chair of the cardiology department at the Erasmus MC, Rotterdam. Prof. de Boer is co-author of >600 articles in international peer reviewed scientific journals. In 2022, he belonged to the top 1% of most cited scientists in the field of Medicine (Web of Science).

Research focus and highlights

His main research focus is on fundamental, translational and clinical research in heart failure. In particular, he studied the interaction between heart failure and diabetes, myocardial fibrosis  and biomarkers. For this, he founded a research group with skilled and enthusiastic cardiovascular investigators  with medical, biological and pharmacological backgrounds.  Several of his basic and translational observations were transformed in clinical programs, e.g. the use of oral antidiabetic drugs in non-diabetic heart failure patients and the development of galectin-3 based clinical work-up and treatments.

The originality and quality of his work led to support by the Netherlands Organization for Scientific Research (NWO), which granted him VENI (2007) and VIDI (2013) grants. He furthermore was supported by numerous personal and consortium grants from the Netherlands Heart Foundation.

In 2018 his group published a seminal paper that for the first time described that heart failure is causally involved in the development of cancer – so called reverse cardio-oncology. This article received several accolades, including the Joe Loscalzo Award award for best basic and translational paper in the leading CV journal, Circulation. The value of this work was recognized by the European research Council (ERC) that awarded de Boer with a prestigious ERC Consolidator Grant (SECRETE-HF) on this topic.  

As a clinical PI and co-investigator, Prof. de Boer has been involved in a large number of hallmark RCTs in the heart failure arena. He was member of the DAPA-HF and DELIVER study teams that pioneered the use of the SGLT2 inhibitor dapagliflozin, an anti-diabetic drug, in heart failure. The main papers both were published in the New England Journal of Medicine, and many secondary analyses helped to re-shape the face of contemporary heart failure treatment. Recently, the Rotterdam team finished and published in the Lancet a novel method to monitor remotely patients with heart failure, and it is expected this will change the treatment in the Netherlands.

Network and embedding

Prof. de Boer is well-embedded at the National and International level. De Boer currently is the President of the Dutch Cardiac Society (NVVC). He devoted considerable time to collaborative research and to organization of heart failure care in the Netherlands (being the ex-president of the working group on heart failure), as well as in Europe, where he was board member of the Heart failure Association (HFA) between 2014-2020 and served on several committees of the European Society of Cardiology (ESC) and other cardiology societies.  De Boer is a frequently invited speaker on national and international conferences, and serves on a large number of boards and committees.

• Heart Failure, HFpEF
• Biomarkers
• Cardio-oncology

• 1995-1996 Research fellow, University of Utah, SLC, USA.
• 1998 M.D. degree, University of Groningen, the Netherlands.
• 2002 Ph.D. degree, department of Cardiology, University Medical Center Groningen, the Netherlands. Title: Heart Failure, neurohormonal activation & angiogenesis. Promotores Prof. DJ van Veldhuisen & WH van Gilst
• 2002-2003 Postdoctoral researcher, Harvard Medical School, Brigham & Women’s Hospital, Boston, USA
• 2008 Cardiologist and Assistant Professor, University Medical Center Groningen, the Netherlands
• 2010 Associate professor, University Medical Center Groningen, the Netherlands
• 2013 Professor of Translational Cardiology, University Medical Center Groningen, the Netherlands
• 2013 Chair, Experimental Cardiology, University Medical Center Groningen, the Netherlands
• 2022 Head of department of Cardiology, Erasmus MC Rotterdam, the Netherlands. 

Publications

>600 publications and 20 book chapters (July 2023). 29000 citations (Web of Science) resulting in an H index = 88; 1 patent.

Listed below are some relevant recent publications:

Biomarkers:

• de Boer RA, Nayor M, deFilippi CR, Enserro D, Bhambhani V, Kizer JR, Blaha MJ, Brouwers FP, Cushman M, Lima JAC, Bahrami H, van der Harst P, Wang TJ, Gansevoort RT, Fox CS, Gaggin HK, Kop WJ, Liu K, Vasan RS, Psaty BM, Lee DS, Hillege HL, Bartz TM, Benjamin EJ, Chan C, Allison M, Gardin JM, Januzzi JL Jr, Shah SJ, Levy D, Herrington DM, Larson MG, van Gilst WH, Gottdiener JS, Bertoni AG, Ho JE. Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. JAMA Cardiol. 2018 Mar 1;3(3):215-224. doi: 10.1001/jamacardio.2017.4987.
• Suthahar N, Meijers WC, Silljé HHW, Ho JE, Liu FT, de Boer RA. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update. Theranostics. 2018 Jan 1;8(3):593-609. doi: 10.7150/thno.22196.
• Suthahar N, Lau ES, Blaha MJ, Paniagua SM, Larson MG, Psaty BM, Benjamin EJ, Allison MA, Bartz TM, Januzzi JL Jr, Levy D, Meems LMG, Bakker SJL, Lima JAC, Cushman M, Lee DS, Wang TJ, deFilippi CR, Herrington DM, Nayor M, Vasan RS, Gardin JM, Kizer JR, Bertoni AG, Allen NB, Gansevoort RT, Shah SJ, Gottdiener JS, Ho JE, de Boer RA. Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident Heart Failure. J Am Coll Cardiol. 2020 Sep 22;76(12):1455-1465. doi: 10.1016/j.jacc.2020.07.044.
• Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, Fonarow GC, Greenberg B, Januzzi JL Jr, Kiernan MS, Liu PP, Wang TJ, Yancy CW, Zile MR; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Council on Quality of Care and Outcomes Research. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017 May 30;135(22):e1054-e1091. doi: 10.1161/CIR.0000000000000490. Epub 2017 Apr 26. Erratum in: Circulation. 2017 Nov 7;136(19):e345.
• Lau ES, Paniagua SM, Liu E, Jovani M, Li SX, Takvorian K, Suthahar N, Cheng S, Splansky GL, Januzzi JL Jr, Wang TJ, Vasan RS, Kreger B, Larson MG, Levy D, de Boer RA, Ho JE. Cardiovascular Risk Factors are Associated with Future Cancer. JACC CardioOncol. 2021 Mar;3(1):48-58. doi: 10.1016/j.jaccao.2020.12.003. Epub 2021 Mar 16.

Incident Heart Failure:

• Suthahar N, Wang D, Aboumsallem JP, Shi C, de Wit S, Liu EE, Lau ES, Bakker SJL, Gansevoort RT, van der Vegt B, Jovani M, Kreger BE, Lee Splansky G, Benjamin EJ, Vasan RS, Larson MG, Levy D, Ho JE, de Boer RA. Association of Initial and Longitudinal Changes in C-reactive Protein With the Risk of Cardiovascular Disease, Cancer, and Mortality. Mayo Clin Proc. 2023 Apr;98(4):549-558. doi: 10.1016/j.mayocp.2022.10.013.
• Tromp J, Paniagua SMA, Lau ES, Allen NB, Blaha MJ, Gansevoort RT, Hillege HL, Lee DE, Levy D, Vasan RS, van der Harst P, van Gilst WH, Larson MG, Shah SJ, de Boer RA, Lam CSP, Ho JE. Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ. 2021 Mar 23;372:n461. doi: 10.1136/bmj.n461.
• Suthahar N, Lau ES, Blaha MJ, Paniagua SM, Larson MG, Psaty BM, Benjamin EJ, Allison MA, Bartz TM, Januzzi JL Jr, Levy D, Meems LMG, Bakker SJL, Lima JAC, Cushman M, Lee DS, Wang TJ, deFilippi CR, Herrington DM, Nayor M, Vasan RS, Gardin JM, Kizer JR, Bertoni AG, Allen NB, Gansevoort RT, Shah SJ, Gottdiener JS, Ho JE, de Boer RA. Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident Heart Failure. J Am Coll Cardiol. 2020 Sep 22;76(12):1455-1465. doi: 10.1016/j.jacc.2020.07.044.
• Suthahar N, Meijers WC, Ho JE, Gansevoort RT, Voors AA, van der Meer P, Bakker SJL, Heymans S, van Empel V, Schroen B, van der Harst P, van Veldhuisen DJ, de Boer RA. Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population. Eur J Heart Fail. 2018 Aug;20(8):1205-1214. doi: 10.1002/ejhf.1209. Epub 2018 Jun 1.
• Ho JE, Enserro D, Brouwers FP, Kizer JR, Shah SJ, Psaty BM, Bartz TM, Santhanakrishnan R, Lee DS, Chan C, Liu K, Blaha MJ, Hillege HL, van der Harst P, van Gilst WH, Kop WJ, Gansevoort RT, Vasan RS, Gardin JM, Levy D, Gottdiener JS, de Boer RA, Larson MG. Predicting Heart Failure With Preserved and Reduced Ejection Fraction: The International Collaboration on Heart Failure Subtypes. Circ Heart Fail. 2016 Jun;9(6):10.1161/CIRCHEARTFAILURE.115.003116 e003116. doi: 10.1161/CIRCHEARTFAILURE.115.003116.

Cardiomyopathies:

• de Brouwer R, Te Rijdt WP, Hoorntje ET, Amin A, Asselbergs FW, Cox MGPJ, van der Heijden JF, Hillege H, Karper JC, Mahmoud B, van der Meer P, Oomen A, Te Riele ASJM, Silljé HHW, Tan HL, van Tintelen JP, van Veldhuisen DJ, Westenbrink BD, Wiesfeld ACP, Willems TP, van der Zwaag PA, Wilde AAM, de Boer RA, van den Berg MP. A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers. Eur Heart J. 2023 May 20:ehad292. doi: 10.1093/eurheartj/ehad292. Epub ahead of print. PMID: 37210081.
• Tadros R, Francis C, Xu X, Vermeer AMC, Harper AR, Huurman R, Kelu Bisabu K, Walsh R, Hoorntje ET, Te Rijdt WP, Buchan RJ, van Velzen HG, van Slegtenhorst MA, Vermeulen JM, Offerhaus JA, Bai W, de Marvao A, Lahrouchi N, Beekman L, Karper JC, Veldink JH, Kayvanpour E, Pantazis A, Baksi AJ, Whiffin N, Mazzarotto F, Sloane G, Suzuki H, Schneider-Luftman D, Elliott P, Richard P, Ader F, Villard E, Lichtner P, Meitinger T, Tanck MWT, van Tintelen JP, Thain A, McCarty D, Hegele RA, Roberts JD, Amyot J, Dubé MP, Cadrin-Tourigny J, Giraldeau G, L'Allier PL, Garceau P, Tardif JC, Boekholdt SM, Lumbers RT, Asselbergs FW, Barton PJR, Cook SA, Prasad SK, O'Regan DP, van der Velden J, Verweij KJH, Talajic M, Lettre G, Pinto YM, Meder B, Charron P, de Boer RA, Christiaans I, Michels M, Wilde AAM, Watkins H, Matthews PM, Ware JS, Bezzina CR. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat Genet. 2021 Feb;53(2):128-134. doi: 10.1038/s41588-020-00762-2. Epub 2021 Jan 25.
• Seferović PM, Polovina M, Bauersachs J, Arad M, Ben Gal T, Lund LH, Felix SB, Arbustini E, Caforio ALP, Farmakis D, Filippatos GS, Gialafos E, Kanjuh V, Krljanac G, Limongelli G, Linhart A, Lyon AR, Maksimović R, Miličić D, Milinković I, Noutsias M, Oto A, Oto Ö, Pavlović SU, Piepoli MF, Ristić AD, Rosano GMC, Seggewiss H, Ašanin M, Seferović JP, Ruschitzka F, Čelutkiene J, Jaarsma T, Mueller C, Moura B, Hill L, Volterrani M, Lopatin Y, Metra M, Backs J, Mullens W, Chioncel O, de Boer RA, Anker S, Rapezzi C, Coats AJS, Tschöpe C.  Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019 May;21(5):553-576. doi: 10.1002/ejhf.1461. Epub 2019 Apr 16.
• Eijgenraam TR, Boogerd CJ, Stege NM, Oliveira Nunes Teixeira V, Dokter MM, Schmidt LE, Yin X, Theofilatos K, Mayr M, van der Meer P, van Rooij E, van der Velden J, Silljé HHW, de Boer RA. Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy. Circ Heart Fail. 2021 Nov;14(11):e008532. doi: 10.1161/CIRCHEARTFAILURE.121.008532. Epub 2021 Sep 30.

de Boer RA, Heymans S, Backs J, Carrier L, Coats AJS, Dimmeler S, Eschenhagen T, Filippatos G, Gepstein L, Hulot JS, Knöll R, Kupatt C, Linke WA, Seidman CE, Tocchetti CG, van der Velden J, Walsh R, Seferovic PM, Thum T. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). Eur J Heart Fail. 2022 Mar;24(3):406-420. doi: 10.1002/ejhf.2414. Epub 2022 Jan 14

Cardio-oncology: 

• Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ, Westenbrink BD, van der Meer P, Silljé HHW, de Boer RA. Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation. 2018 Aug 14;138(7):678-691. doi: 10.1161/CIRCULATIONAHA.117.030816.
• de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and heart disease: associations and relations. Eur J Heart Fail. 2019 Dec;21(12):1515-1525. doi: 10.1002/ejhf.1539. Epub 2019 Jul 18.
• Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. Cardiovasc Res. 2019 Apr 15;115(5):844-853. doi: 10.1093/cvr/cvz035.
• Karlstaedt A, Moslehi J, de Boer RA. Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer. Nat Rev Cardiol. 2022 Jun;19(6):414-425. doi: 10.1038/s41569-022-00698-6. Epub 2022 Apr 19.
• Asnani A, Moslehi JJ, Adhikari BB, Baik AH, Beyer AM, de Boer RA, Ghigo A, Grumbach IM, Jain S, Zhu H; American Heart Association Council on Basic Cardiovascular Sciences; Cardio-Oncology Science Subcommittee of Council on Genomic and Precision Medicine and Council on Clinical Cardiology; Council on Peripheral Vascular Disease; and Council on Arteriosclerosis, Thrombosis and Vascular Biology. Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association. Circ Res. 2021 Jun 25;129(1):e21-e34. doi: 10.1161/RES.0000000000000473. Epub 2021 May 3.
• Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S, Barac A, Stanway S, Moslehi J, Suter TM, Ky B, Štěrba M, Cardinale D, Cohen-Solal A, Tocchetti CG, Farmakis D, Bergler-Klein J, Anker MS, Von Haehling S, Belenkov Y, Iakobishvili Z, Maack C, Ciardiello F, Ruschitzka F, Coats AJS, Seferovic P, Lainscak M, Piepoli MF, Chioncel O, Bax J, Hulot JS, Skouri H, Hägler-Laube ES, Asteggiano R, Fernandez TL, de Boer RA, Lyon AR. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020 Nov;22(11):1966-1983. doi: 10.1002/ejhf.2017. Epub 2020 Oct 20.
• Aboumsallem JP, Moslehi J, de Boer RA. Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease. J Am Heart Assoc. 2020 Jan 21;9(2):e013754. doi: 10.1161/JAHA.119.013754. Epub 2020 Jan 21.
• Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESCScientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244

Diabetes: 

• Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018 May;20(5):853-872. doi: 10.1002/ejhf.1170. Epub 2018 Mar 8.
• Lexis CP, van der Horst IC, Lipsic E, Wieringa WG, de Boer RA, van den Heuvel AF, van der Werf HW, Schurer RA, Pundziute G, Tan ES, Nieuwland W, Willemsen HM, Dorhout B, Molmans BH, van der Horst-Schrivers AN, Wolffenbuttel BH, ter Horst GJ, van Rossum AC, Tijssen JG, Hillege HL, de Smet BJ, van der Harst P, van Veldhuisen DJ; GIPS-III Investigators. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA. 2014 Apr 16;311(15):1526-35. doi: 10.1001/jama.2014.3315. PMID: 24687169.
• Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Silljé HH, de Boer RA. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. 2011 Aug;301(2):H459-68. doi: 10.1152/ajpheart.00054.2011. Epub 2011 May 13.
• El Messaoudi S, Rongen GA, de Boer RA, Riksen NP. The cardioprotective effects of metformin. Curr Opin Lipidol. 2011 Dec;22(6):445-53. doi: 10.1097/MOL.0b013e32834ae1a7. PMID: 21897229
• Withaar C, Meems LMG, Markousis-Mavrogenis G, Boogerd CJ, Silljé HHW, Schouten EM, Dokter MM, Voors AA, Westenbrink BD, Lam CSP, de Boer RA. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovasc Res. 2021 Jul 27;117(9):2108-2124. doi: 10.1093/cvr/cvaa256. PMID: 32871009; PMCID: PMC8318109.
• Withaar C, Meems LMG, Nollet EE, Schouten EM, Schroeder MA, Knudsen LB, Niss K, Madsen CT, HoeglA, Mazzoni G, van der Velden J, Lam CSP, Silljé HHW, de Boer RA. Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF.JACC Basic Transl Sci. 2023 ePub

Clinical trails: 

• Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27.
• McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
• Brugts JJ, Radhoe SP, Clephas PRD, Aydin D, van Gent MWF, Szymanski MK, Rienstra M, van den Heuvel MH, da Fonseca CA, Linssen GCM, Borleffs CJW, Boersma E, Asselbergs FW, Mosterd A, Brunner-La Rocca HP, de Boer RA; MONITOR-HF investigators. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet. 2023 Jun 24;401(10394):2113-2123. doi: 10.1016/S0140-6736(23)00923-6. Epub 2023 May 20. Erratum in: Lancet. 2023 Jun 24;401(10394):2112.
• Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, McMurray JJV, Solomon SD. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022 Sep 3;400(10354):757-767. doi: 10.1016/S0140-6736(22)01429-5. Epub 2022 Aug 27. Erratum in: Lancet. 2023 Jan 14;401(10371):104.

• Teacher at post graduate training of heart failure.
• Lecturer on several (inter)national meetings of scientific and medical societies.

2020 – onwards         President elect Dutch Cardiac Society (NVVC)
2020 – onwards         Liaison Officer, ESC Council  on Cardio-Oncology
2018 – 2020                Member e-Education committee of the European Society of Cardiology                                          (ESC)
2018 – 2020                Member Education Committee of the ESC
2017 – 2019                 Member VENI committee (Netherlands Organization for Scientific                                                    research, NWO)
2016 – 2020                Member Advocacy Committee of the ESC
2016 – 2018                 Board member van de Heart Failure Association (HFA), Chair of the Basic                                        Section
2016 – 2020                Coordinator HFA Study Group Heart Failure with preserved ejection                                                fraction
2016 – onwards         Fellow of the American Heart Association (FAHA)
2016 – 2020               Member Study Group Onco-Cardiology (HFA)
2014 – 2019                Chair, working group Heart failure of the Dutch Cardiac Society (NVVC)
2012 – 2016                Member of the Translational Committee of the HFA
2014 – 2020               Board member Heart Failure Association (HFA) van de ESC, Basic Section
2011 – 2014                 Treasurer, working group Heart failure of the Dutch Cardiac Society                                                 (NVVC)
2010 – onwards        Fellow of the European Society of Cardiology (FESC)
2002 – onwards       Member, American Heart Association (AHA), Council Basic                                                                  Cardiovascular Research
2002 – onwards       Member, American College of Cardiology (ACC)
1998 – onwards        Member, Dutch Cardiac Society (NVVC)

2021    DOUBLE-DOSE (Determinants susceptibility inherited cardiomyopathy: towards novel               approaches); Netherlands Heart Foundation; (Project leader: € 3 Million)

2019    Secreted factors in cardiac remodelling provoke tumorigenesis and end-organ                             damage in heart failure (SECRETE-HF); European Research Council (ERC)-                                     Consolidator,  € 2 Million).
2018    Predict Sudden Cardiac Death-2; Netherlands Heart Foundation; (PI: € 300,000)
2017    Sex differences in tHE Pathophysiology, moleculaR processes and biomarker levels to                 prEDICT new onset Heart Failure in women (SHE-PREDICTS-HF) Netherlands Heart                   Foundation; (Project leader: € 1.000,000)
2017    Reviving Early Diagnosis of CardioVascular Disease (RED-CVD) Netherlands Heart                         Foundation; (PI: € 1.000,000)
2017    R14Del Phosholamban mutation: generation of Tg mouse (Netherlands Heart                               Institute)  (Project leader: € 50,000)
2016    Apixaban in cardiac remodelling (Bristol Meyers Squibb) (PI: € 130,000)
2015    MPO inhibition in obesity-induced HF. AstraZeneca (Project leader: € 75,000)
2014    DOSIS (Determinants of susceptibility in inherited cardiomyopathy: towards novel                       approaches); Netherlands Heart Foundation; (Project leader: € 1.500,000)
2014    Effects of MPO inhibition on cardiac remodeling. AstraZeneca (€ 62,000)
2013    European Lead Factory/Innovative Medicines Initiative (IMI): Galectin-3 inhibitors for                   the treatment of heart failure (Project Leader; € 750,000)
2013    Galectin-3 as a Modifiable Risk Factor, NWO-VIDI grant (Project leader; € 800,000)
2010    Galectin-3 in Heart Failure Development (€ 200,000); BG Medicine (Waltham USA)
2009    (Pro)renin receptor in cardiac remodeling. NWO-VENI grant (€ 300,000)
2009    Galectin-3 in the general population (€ 90,000) BG Medicine, Inc. (Waltham, USA)
2008    Vitamin D supplementation in Heart Failure (Netherlands Foundation for                                      Cardiovascular Excellence (NFCVE; € 80,000)
2008    Vitamin D in cardiac remodeling  (€ 75,000); Abbott Laboratories (Chicago, USA)
2007    Netherlands Heart Foundation (Junior staff member; € 220, 000) ; Renin regulation                  in  Heart Failure
2004    Netherlands Heart Foundation (Dr. E. Dekker program) (€ 150,000) ; The role of                            nuclear hormone receptors in renin regulation
2006    Netherlands Heart Foundation: Reviewer of the year
2002    Interuniversity Cardiology Institute Netherlands (€ 45,400), personal stipend